{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:36:34Z","timestamp":1794375394526,"version":"4.9.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41584-025-01279-w","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:47:33Z","timestamp":1753706853000},"page":"546-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-0932","authenticated-orcid":false,"given":"Maurizio","family":"Cutolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Soldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-0306","authenticated-orcid":false,"given":"Emanuele","family":"Gotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Hysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"1279_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-031-65944-7_4","volume":"74","author":"L Dillac","year":"2024","unstructured":"Dillac, L., El Dika, L., Ullah, R., Kubiak, J. Z. & Kloc, M. Macrophage cell cycle. Results Probl. Cell Differ. 74, 119\u2013134 (2024).","journal-title":"Results Probl. Cell Differ."},{"key":"1279_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal. Transduct. Target. Ther. 8, 207 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1279_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8821610","volume":"2023","author":"Y Peng","year":"2023","unstructured":"Peng, Y. et al. Regulatory mechanism of M1\/M2 macrophage polarization in the development of autoimmune diseases. Mediators Inflamm. 2023, 8821610 (2023).","journal-title":"Mediators Inflamm."},{"key":"1279_CR4","doi-asserted-by":"publisher","first-page":"867260","DOI":"10.3389\/fimmu.2022.867260","volume":"13","author":"M Cutolo","year":"2022","unstructured":"Cutolo, M., Campitiello, R., Gotelli, E. & Soldano, S. The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis. Front. Immunol. 13, 867260 (2022).","journal-title":"Front. Immunol."},{"key":"1279_CR5","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/ijms23031496","volume":"23","author":"Y Degbo\u00e9","year":"2022","unstructured":"Degbo\u00e9, Y., Poupot, R. & Poupot, M. Repolarization of unbalanced macrophages: unmet medical need in chronic inflammation and cancer. Int. J. Mol. Sci. 23, 1496 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1279_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/intimm\/dxz036","volume":"31","author":"S Hirose","year":"2019","unstructured":"Hirose, S., Lin, Q., Ohtsuji, M., Nishimura, H. & Verbeek, J. S. Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int. Immunol. 31, 687\u2013696 (2019).","journal-title":"Int. Immunol."},{"key":"1279_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41586-023-06002-x","volume":"618","author":"T Lazarov","year":"2023","unstructured":"Lazarov, T., Juarez-Carre\u00f1o, S., Cox, N. & Geissmann, F. Physiology and diseases of tissue-resident macrophages. Nature 618, 698\u2013707 (2023).","journal-title":"Nature"},{"key":"1279_CR8","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. 164, 6166\u20136173 (2000).","journal-title":"J. Immunol."},{"key":"1279_CR9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3390\/ijms26052107","volume":"26","author":"J Brancewicz","year":"2025","unstructured":"Brancewicz, J., W\u00f3jcik, N., Sarnowska, Z., Robak, J. & Kr\u00f3l, M. The multifaceted role of macrophages in biology and diseases. Int. J. Mol. Sci. 26, 2107 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1279_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","volume":"40","author":"J Xue","year":"2014","unstructured":"Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274\u2013288 (2014).","journal-title":"Immunity"},{"key":"1279_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14\u201320 (2014).","journal-title":"Immunity"},{"key":"1279_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1042\/CS20220531","volume":"137","author":"Z Strizova","year":"2023","unstructured":"Strizova, Z. et al. M1\/M2 macrophages and their overlaps \u2014 myth or reality? Clin. Sci. 137, 1067\u20131093 (2023).","journal-title":"Clin. Sci."},{"key":"1279_CR13","doi-asserted-by":"publisher","first-page":"103637","DOI":"10.1016\/j.autrev.2024.103637","volume":"23","author":"R Campitiello","year":"2024","unstructured":"Campitiello, R. et al. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: a systematic review. Autoimmun. Rev. 23, 103637 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1279_CR14","doi-asserted-by":"publisher","first-page":"734008","DOI":"10.3389\/fimmu.2021.734008","volume":"12","author":"MM Ahamada","year":"2021","unstructured":"Ahamada, M. M., Jia, Y. & Wu, X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front. Immunol. 12, 734008 (2021).","journal-title":"Front. Immunol."},{"key":"1279_CR15","doi-asserted-by":"publisher","first-page":"1394108","DOI":"10.3389\/fimmu.2024.1394108","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts. Front. Immunol. 15, 1394108 (2024).","journal-title":"Front. Immunol."},{"key":"1279_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/life15010055","volume":"15","author":"C Chavanisakun","year":"2025","unstructured":"Chavanisakun, C., Keawvichit, R. & Benjakul, N. M1 and M2 macrophage polarization correlates with activity and chronicity indices in lupus nephritis. Life 15, 55 (2025).","journal-title":"Life"},{"key":"1279_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103111","volume":"140","author":"JC Graver","year":"2023","unstructured":"Graver, J. C. et al. Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis. J. Autoimmun. 140, 103111 (2023).","journal-title":"J. Autoimmun."},{"key":"1279_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","volume":"65","author":"AK Rana","year":"2018","unstructured":"Rana, A. K., Li, Y., Dang, Q. & Yang, F. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int. Immunopharmacol. 65, 348\u2013359 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"1279_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41586-019-1471-1","volume":"572","author":"S Culemann","year":"2019","unstructured":"Culemann, S. et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature 572, 670\u2013675 (2019).","journal-title":"Nature"},{"key":"1279_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958\u2013969 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1279_CR21","doi-asserted-by":"publisher","first-page":"860813","DOI":"10.3389\/fmed.2022.860813","volume":"9","author":"C Tenazinha","year":"2022","unstructured":"Tenazinha, C., Barros, R., Fonseca, J. E. & Vieira-Sousa, E. Histopathology of psoriatic arthritis synovium \u2014 a narrative review. Front. Med. 9, 860813 (2022).","journal-title":"Front. Med."},{"key":"1279_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/25785826.2021.1944547","volume":"45","author":"T Agemura","year":"2022","unstructured":"Agemura, T., Hasegawa, T., Yari, S., Kikuta, J. & Ishii, M. Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis. Immunol. Med. 45, 22\u201326 (2022).","journal-title":"Immunol. Med."},{"key":"1279_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","volume":"12","author":"IA Udalova","year":"2016","unstructured":"Udalova, I. A., Mantovani, A. & Feldmann, M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 472\u2013485 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1279_CR24","doi-asserted-by":"publisher","first-page":"102397","DOI":"10.1016\/j.autrev.2019.102397","volume":"18","author":"S Tardito","year":"2019","unstructured":"Tardito, S. et al. Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun. Rev. 18, 102397 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1279_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu, N. & Takayanagi, H. Mechanisms of joint destruction in rheumatoid arthritis \u2014 immune cell\u2013fibroblast\u2013bone interactions. Nat. Rev. Rheumatol. 18, 415\u2013429 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1279_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00011-015-0874-1","volume":"65","author":"S Bashir","year":"2016","unstructured":"Bashir, S., Sharma, Y., Elahi, A. & Khan, F. Macrophage polarization: the link between inflammation and related diseases. Inflamm. Res. 65, 1\u201311 (2016).","journal-title":"Inflamm. Res."},{"key":"1279_CR27","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41590-019-0526-7","volume":"20","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa, T. et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat. Immunol. 20, 1631\u20131643 (2019).","journal-title":"Nat. Immunol."},{"key":"1279_CR28","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/jbmr.2868","volume":"31","author":"L Ib\u00e1\u00f1ez","year":"2016","unstructured":"Ib\u00e1\u00f1ez, L. et al. Inflammatory osteoclasts prime TNF\u03b1-producing CD4+ T cells and express CX3 CR1. J. Bone Min. Res. 31, 1899\u20131908 (2016).","journal-title":"J. Bone Min. Res."},{"key":"1279_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"1279_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"1279_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nri978","volume":"3","author":"S Gordon","year":"2003","unstructured":"Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23\u201335 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"1279_CR32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41584-022-00790-8","volume":"18","author":"M Kurowska-Stolarska","year":"2022","unstructured":"Kurowska-Stolarska, M. & Alivernini, S. Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission. Nat. Rev. Rheumatol. 18, 384\u2013397 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1279_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41591-024-02818-w","volume":"30","author":"S Alivernini","year":"2024","unstructured":"Alivernini, S., Ca\u00f1ete, J. D., Bacardit, J. & Kurowska-Stolarska, M. Using explainable artificial intelligence to predict and forestall flare in rheumatoid arthritis. Nat. Med. 30, 925\u2013926 (2024).","journal-title":"Nat. Med."},{"key":"1279_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun, S. C. The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545\u2013558 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1279_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal. Transduct. Target. Ther. 9, 53 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1279_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/JME-21-0019","volume":"69","author":"X Peng","year":"2022","unstructured":"Peng, X. et al. miR-146a promotes M2 macrophage polarization and accelerates diabetic wound healing by inhibiting the TLR4\/NF-\u03baB axis. J. Mol. Endocrinol. 69, 315\u2013327 (2022).","journal-title":"J. Mol. Endocrinol."},{"key":"1279_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-024-03351-4","volume":"26","author":"C \u00c7ubuk","year":"2024","unstructured":"\u00c7ubuk, C. et al. Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes. Arthritis Res. Ther. 26, 120 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.21037\/atm-22-142","volume":"10","author":"Y Zhuang","year":"2022","unstructured":"Zhuang, Y. et al. A narrative review of the role of the Notch signaling pathway in rheumatoid arthritis. Ann. Transl. Med. 10, 371 (2022).","journal-title":"Ann. Transl. Med."},{"key":"1279_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859400","volume":"13","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Epigenetic regulation in the pathogenesis of rheumatoid arthritis. Front. Immunol. 13, 859400 (2022).","journal-title":"Front. Immunol."},{"key":"1279_CR40","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1096\/fj.201902379R","volume":"34","author":"X Li","year":"2020","unstructured":"Li, X. et al. LncRNA Dnmt3aos regulates Dnmt3a expression leading to aberrant DNA methylation in macrophage polarization. FASEB J. 34, 5077\u20135091 (2020).","journal-title":"FASEB J."},{"key":"1279_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00018-022-04331-0","volume":"79","author":"Y Zheng","year":"2022","unstructured":"Zheng, Y. et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-\u03baB\/IL-6 signaling pathway. Cell Mol. Life Sci. 79, 311 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"1279_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/08820139.2024.2302828","volume":"53","author":"X Liu","year":"2024","unstructured":"Liu, X., Xiang, R., Fang, X., Wang, G. & Zhou, Y. Advances in metabolic regulation of macrophage polarization state. Immunol. Invest. 53, 416\u2013436 (2024).","journal-title":"Immunol. Invest."},{"key":"1279_CR43","doi-asserted-by":"publisher","first-page":"1444964","DOI":"10.3389\/fimmu.2024.1444964","volume":"15","author":"Z Ge","year":"2024","unstructured":"Ge, Z., Chen, Y., Ma, L., Hu, F. & Xie, L. Macrophage polarization and its impact on idiopathic pulmonary fibrosis. Front. Immunol. 15, 1444964 (2024).","journal-title":"Front. Immunol."},{"key":"1279_CR44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.imbio.2017.02.006","volume":"222","author":"EB Lurier","year":"2017","unstructured":"Lurier, E. B. et al. Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. Immunobiology 222, 847\u2013856 (2017).","journal-title":"Immunobiology"},{"key":"1279_CR45","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.4049\/jimmunol.1200662","volume":"189","author":"G Zizzo","year":"2012","unstructured":"Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J. Immunol. 189, 3508\u20133520 (2012).","journal-title":"J. Immunol."},{"key":"1279_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo, Q. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 6, 15 (2018).","journal-title":"Bone Res."},{"key":"1279_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fimmu.2019.00003","volume":"10","author":"Y Degbo\u00e9","year":"2019","unstructured":"Degbo\u00e9, Y. et al. Polarization of rheumatoid macrophages by TNF targeting through an IL-10\/STAT3 mechanism. Front. Immunol. 10, 3 (2019).","journal-title":"Front. Immunol."},{"key":"1279_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13075-021-02691-9","volume":"23","author":"M Cutolo","year":"2021","unstructured":"Cutolo, M. et al. CTLA4-Ig treatment induces M1\u2013M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients. Arthritis Res. Ther. 23, 306 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR49","first-page":"943","volume":"31","author":"M Cutolo","year":"2013","unstructured":"Cutolo, M. et al. Intracellular NF-kB-decrease and IKB\u03b1 increase in human macrophages following CTLA4-Ig treatment. Clin. Exp. Rheumatol. 31, 943\u2013946 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/ar2865","volume":"11","author":"M Cutolo","year":"2009","unstructured":"Cutolo, M. et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11, R176 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR51","first-page":"500","volume":"34","author":"M Cutolo","year":"2016","unstructured":"Cutolo, M. et al. Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages. Clin. Exp. Rheumatol. 34, 500\u2013506 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00018-024-05196-1","volume":"81","author":"B L\u00f3pez-Navarro","year":"2024","unstructured":"L\u00f3pez-Navarro, B. et al. Macrophage re-programming by JAK inhibitors relies on MAFB. Cell Mol. Life Sci. 81, 152 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"1279_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41584-023-00944-2","volume":"19","author":"M Cutolo","year":"2023","unstructured":"Cutolo, M., Smith, V., Paolino, S. & Gotelli, E. Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat. Rev. Rheumatol. 19, 265\u2013287 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1279_CR54","first-page":"934","volume":"30","author":"B Villaggio","year":"2012","unstructured":"Villaggio, B., Soldano, S. & Cutolo, M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin. Exp. Rheumatol. 30, 934\u2013938 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2023.106251","volume":"228","author":"W Zhu","year":"2023","unstructured":"Zhu, W. et al. 1,25-Dihydroxyvitamin D regulates macrophage activation through FBP1\/PKR and ameliorates arthritis in TNF-transgenic mice. J. Steroid Biochem. Mol. Biol. 228, 106251 (2023).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1279_CR56","doi-asserted-by":"publisher","first-page":"104394","DOI":"10.1016\/j.phrs.2019.104394","volume":"148","author":"R Talotta","year":"2019","unstructured":"Talotta, R., Atzeni, F., Sarzi-Puttini, P. & Masala, I. F. Psoriatic arthritis: from pathogenesis to pharmacologic management. Pharmacol. Res. 148, 104394 (2019).","journal-title":"Pharmacol. Res."},{"key":"1279_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/gene.2009.11","volume":"10","author":"JT Elder","year":"2009","unstructured":"Elder, J. T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes. Immun. 10, 201\u2013209 (2009).","journal-title":"Genes. Immun."},{"key":"1279_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613975","volume":"11","author":"S Fuentelsaz-Romero","year":"2020","unstructured":"Fuentelsaz-Romero, S. et al. GM-CSF expression and macrophage polarization in joints of undifferentiated arthritis patients evolving to rheumatoid arthritis or psoriatic arthritis. Front. Immunol. 11, 613975 (2020).","journal-title":"Front. Immunol."},{"key":"1279_CR59","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/art.24406","volume":"60","author":"B Vandooren","year":"2009","unstructured":"Vandooren, B. et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 60, 966\u2013975 (2009).","journal-title":"Arthritis Rheum."},{"key":"1279_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/path.4466","volume":"235","author":"B Soler Palacios","year":"2015","unstructured":"Soler Palacios, B. et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J. Pathol. 235, 515\u2013526 (2015).","journal-title":"J. Pathol."},{"key":"1279_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1279_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.776879","volume":"12","author":"S Fuentelsaz-Romero","year":"2021","unstructured":"Fuentelsaz-Romero, S. et al. The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis. Front. Immunol. 12, 776879 (2021).","journal-title":"Front. Immunol."},{"key":"1279_CR63","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2021-220280","volume":"80","author":"N Yager","year":"2021","unstructured":"Yager, N. et al. Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid. Ann. Rheum. Dis. 80, 1559\u20131567 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR64","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo, M., Soldano, S. & Smith, V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert. Rev. Clin. Immunol. 15, 753\u2013764 (2019).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1279_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166433","volume":"11","author":"S Soldano","year":"2016","unstructured":"Soldano, S. et al. Alternatively activated (M2) macrophage phenotype is inducible by endothelin-1 in cultured human macrophages. PLoS One 11, e0166433 (2016).","journal-title":"PLoS One"},{"key":"1279_CR66","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/rheumatology\/keac410","volume":"62","author":"Y Al-Adwi","year":"2023","unstructured":"Al-Adwi, Y. et al. Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology 62, 535\u2013545 (2023).","journal-title":"Rheumatology"},{"key":"1279_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16206","volume":"9","author":"M Hu","year":"2023","unstructured":"Hu, M. et al. M2 macrophage polarization in systemic sclerosis fibrosis: pathogenic mechanisms and therapeutic effects. Heliyon 9, e16206 (2023).","journal-title":"Heliyon"},{"key":"1279_CR68","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jid.2021.02.015","volume":"141","author":"Y Ototake","year":"2021","unstructured":"Ototake, Y. et al. Downregulated IRF8 in monocytes and macrophages of patients with systemic sclerosis may aggravate the fibrotic phenotype. J. Invest. Dermatol. 141, 1954\u20131963 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"1279_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281881","volume":"18","author":"M Suzuki","year":"2023","unstructured":"Suzuki, M. et al. Periostin \u2014 an inducer of pro-fibrotic phenotype in monocytes and monocyte-derived macrophages in systemic sclerosis. PLoS ONE 18, e0281881 (2023).","journal-title":"PLoS ONE"},{"key":"1279_CR70","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.41243","volume":"72","author":"R Bhandari","year":"2020","unstructured":"Bhandari, R. et al. Profibrotic activation of human macrophages in systemic sclerosis. Arthritis Rheumatol. 72, 1160\u20131169 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1279_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0300-8","volume":"16","author":"J Hou","year":"2018","unstructured":"Hou, J. et al. M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis. Cell Commun. Signal. 16, 89 (2018).","journal-title":"Cell Commun. Signal."},{"key":"1279_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/ar3066","volume":"12","author":"N Higashi-Kuwata","year":"2010","unstructured":"Higashi-Kuwata, N. et al. Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res. Ther. 12, R128 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-010-1691-z","volume":"32","author":"W Nakayama","year":"2012","unstructured":"Nakayama, W. et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol. Int. 32, 403\u2013407 (2012).","journal-title":"Rheumatol. Int."},{"key":"1279_CR74","doi-asserted-by":"publisher","first-page":"8509583","DOI":"10.1155\/2018\/8509583","volume":"2018","author":"C Frantz","year":"2018","unstructured":"Frantz, C., Pezet, S., Avouac, J. & Allanore, Y. Soluble CD163 as a potential biomarker in systemic sclerosis. Dis. Markers 2018, 8509583 (2018).","journal-title":"Dis. Markers"},{"key":"1279_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004005","volume":"11","author":"JM Mahoney","year":"2015","unstructured":"Mahoney, J. M. et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput. Biol. 11, e1004005 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"1279_CR76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"1279_CR77","doi-asserted-by":"publisher","first-page":"L495","DOI":"10.1152\/ajplung.00458.2021","volume":"322","author":"A Bhattacharyya","year":"2022","unstructured":"Bhattacharyya, A. et al. IL10 trains macrophage profibrotic function after lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 322, L495\u2013L502 (2022).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1279_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug, B. et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann. Rheum. Dis. 79, 379\u2013386 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.41813","volume":"74","author":"D Xue","year":"2022","unstructured":"Xue, D. et al. Expansion of Fc\u03b3 receptor IIIa-positive macrophages, ficolin 1-positive monocyte-derived dendritic cells, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis. Arthritis Rheumatol. 74, 329\u2013341 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1279_CR80","doi-asserted-by":"publisher","first-page":"11995","DOI":"10.3390\/ijms241511995","volume":"24","author":"CC Tseng","year":"2023","unstructured":"Tseng, C. C. et al. The role of macrophages in connective tissue disease-associated interstitial lung disease: focusing on molecular mechanisms and potential treatment strategies. Int. J. Mol. Sci. 24, 11995 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1279_CR81","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/labinvest.2010.73","volume":"90","author":"SK Mathai","year":"2010","unstructured":"Mathai, S. K. et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90, 812\u2013823 (2010).","journal-title":"Lab. Invest."},{"key":"1279_CR82","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2010.06.017","volume":"137","author":"DV Pechkovsky","year":"2010","unstructured":"Pechkovsky, D. V. et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 137, 89\u2013101 (2010).","journal-title":"Clin. Immunol."},{"key":"1279_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642891","volume":"12","author":"M Rudnik","year":"2021","unstructured":"Rudnik, M. et al. Elevated fibronectin levels in profibrotic CD14+ monocytes and CD14+ macrophages in systemic sclerosis. Front. Immunol. 12, 642891 (2021).","journal-title":"Front. Immunol."},{"key":"1279_CR84","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/art.42286","volume":"74","author":"A Papazoglou","year":"2022","unstructured":"Papazoglou, A. et al. Epigenetic regulation of profibrotic macrophages in systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 74, 2003\u20132014 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1279_CR85","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/2397198319838140","volume":"4","author":"H Yasuoka","year":"2019","unstructured":"Yasuoka, H. et al. Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: a potential role of M2 polarization. J. Scleroderma Relat. Disord. 4, 137\u2013148 (2019).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1279_CR86","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1165\/rcmb.2022-0301OC","volume":"69","author":"H Mattoo","year":"2023","unstructured":"Mattoo, H. et al. Molecular features and stages of pulmonary fibrosis driven by type 2 inflammation. Am. J. Respir. Cell Mol. Biol. 69, 404\u2013421 (2023).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1279_CR87","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jacbts.2024.08.008","volume":"9","author":"XM Jones","year":"2024","unstructured":"Jones, X. M. et al. Macrophages contribute to cardiac fibrosis and diastolic dysfunction in systemic sclerosis. JACC Basic. Transl. Sci. 9, 1432\u20131434 (2024).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1279_CR88","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1136\/annrheumdis-2018-213648","volume":"77","author":"S Soldano","year":"2018","unstructured":"Soldano, S. et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann. Rheum. Dis. 77, 1842\u20131845 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR89","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12931-018-0891-z","volume":"19","author":"AC Trombetta","year":"2018","unstructured":"Trombetta, A. C. et al. A circulating cell population showing both M1 and M2 monocyte\/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir. Res. 19, 186 (2018).","journal-title":"Respir. Res."},{"key":"1279_CR90","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.humimm.2021.03.009","volume":"82","author":"ME Mohamed","year":"2021","unstructured":"Mohamed, M. E. et al. Peripheral cells from patients with systemic sclerosis disease co-expressing M1 and M2 monocyte\/macrophage surface markers: relation to the degree of skin involvement. Hum. Immunol. 82, 634\u2013639 (2021).","journal-title":"Hum. Immunol."},{"key":"1279_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1488867","volume":"15","author":"E Gotelli","year":"2024","unstructured":"Gotelli, E. et al. Prevalence of hybrid TLR4+M2 monocytes\/macrophages in peripheral blood and lung of systemic sclerosis patients with interstitial lung disease. Front. Immunol. 15, 1488867 (2024).","journal-title":"Front. Immunol."},{"key":"1279_CR92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo, F. et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann. Rheum. Dis. 84, 29\u201340 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR93","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1279_CR94","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","volume":"24","author":"FF Rahaghi","year":"2023","unstructured":"Rahaghi, F. F. et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir. Res. 24, 6 (2023).","journal-title":"Respir. Res."},{"key":"1279_CR95","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13075-021-02555-2","volume":"23","author":"M Cutolo","year":"2021","unstructured":"Cutolo, M. et al. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. Arthritis Res. Ther. 23, 205 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-024-03308-7","volume":"26","author":"S Soldano","year":"2024","unstructured":"Soldano, S. et al. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease. Arthritis Res. Ther. 26, 74 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963\u2013974 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1279_CR98","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","volume":"21","author":"M Ghazipura","year":"2024","unstructured":"Ghazipura, M. et al. Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann. Am. Thorac. Soc. 21, 328\u2013337 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1279_CR99","doi-asserted-by":"publisher","first-page":"104914","DOI":"10.1016\/j.cellimm.2024.104914","volume":"408","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. The effect of tocilizumab treatment for skin fibrosis by inhibiting CD38+ macrophages in systemic sclerosis. Cell. Immunol. 408, 104914 (2025).","journal-title":"Cell. Immunol."},{"key":"1279_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","volume":"207","author":"C Ma","year":"2019","unstructured":"Ma, C., Xia, Y., Yang, Q. & Zhao, Y. The contribution of macrophages to systemic lupus erythematosus. Clin. Immunol. 207, 1\u20139 (2019).","journal-title":"Clin. Immunol."},{"key":"1279_CR101","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","volume":"67","author":"M Postal","year":"2020","unstructured":"Postal, M. et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol. 67, 87\u201394 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1279_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113136","volume":"142","author":"Y Xiao","year":"2024","unstructured":"Xiao, Y. et al. FASN contributes to the pathogenesis of lupus by promoting TLR-mediated activation of macrophages and dendritic cells. Int. Immunopharmacol. 142, 113136 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"1279_CR103","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","volume":"76","author":"C Maier","year":"2017","unstructured":"Maier, C. et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann. Rheum. Dis. 76, 1133\u20131141 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR104","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat, A. et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem. Pharmacol. 178, 114103 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"1279_CR105","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","volume":"64","author":"A Cole","year":"2023","unstructured":"Cole, A., Ong, V. H. & Denton, C. P. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin. Rev. Allergy Immunol. 64, 378\u2013391 (2023).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1279_CR106","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/acr.25469","volume":"77","author":"D Mongin","year":"2025","unstructured":"Mongin, D. et al. Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research Group database. Arthritis Care Res. 77, 649\u2013657 (2025).","journal-title":"Arthritis Care Res."},{"key":"1279_CR107","doi-asserted-by":"publisher","first-page":"22508","DOI":"10.1021\/acsnano.3c05998","volume":"17","author":"L Luo","year":"2023","unstructured":"Luo, L. et al. Precisely regulating M2 subtype macrophages for renal fibrosis resolution. ACS Nano 17, 22508\u201322526 (2023).","journal-title":"ACS Nano"},{"key":"1279_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1477708","volume":"15","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Roles of macrophages in lupus nephritis. Front. Pharmacol. 15, 1477708 (2024).","journal-title":"Front. Pharmacol."},{"key":"1279_CR109","doi-asserted-by":"publisher","first-page":"103648","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud, L., Chasset, F. & Martin, T. Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun. Rev. 23, 103648 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1279_CR110","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","volume":"57","author":"S Caielli","year":"2024","unstructured":"Caielli, S. et al. Type I IFN drives unconventional IL-1\u03b2 secretion in lupus monocytes. Immunity 57, 2497\u20132513.e12 (2024).","journal-title":"Immunity"},{"key":"1279_CR111","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s13258-022-01308-y","volume":"44","author":"KE Lee","year":"2022","unstructured":"Lee, K. E. et al. The inflammatory signature in monocytes of Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus, revealed by the integrated reactome and drug target analysis. Genes Genomics 44, 1215\u20131229 (2022).","journal-title":"Genes Genomics"},{"key":"1279_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109765","volume":"255","author":"EM Stergioti","year":"2023","unstructured":"Stergioti, E. M. et al. Transcriptomic and proteomic profiling reveals distinct pathogenic features of peripheral non-classical monocytes in systemic lupus erythematosus. Clin. Immunol. 255, 109765 (2023).","journal-title":"Clin. Immunol."},{"key":"1279_CR113","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/03009742.2024.2387483","volume":"54","author":"M Zeisbrich","year":"2024","unstructured":"Zeisbrich, M., Rzepka, R., Finzel, S., Venhoff, N. & Voll, R. E. Macrophage colony-stimulating factor receptor\/CD115+ non-classical monocytes are expanded in systemic lupus erythematosus and associated with lupus nephritis. Scand. J. Rheumatol. 54, 125\u20131341 (2024).","journal-title":"Scand. J. Rheumatol."},{"key":"1279_CR114","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/ard-2023-225433","volume":"83","author":"AG Ferret\u00e9-Bonastre","year":"2024","unstructured":"Ferret\u00e9-Bonastre, A. G. et al. Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus. Ann. Rheum. Dis. 83, 865\u2013878 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35209-1","volume":"13","author":"M Zheng","year":"2022","unstructured":"Zheng, M. et al. Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. Nat. Commun. 13, 7489 (2022).","journal-title":"Nat. Commun."},{"key":"1279_CR116","doi-asserted-by":"publisher","first-page":"579372","DOI":"10.3389\/fimmu.2020.579372","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Increased expression of PPAR-\u03b3 modulates monocytes into a M2-like phenotype in SLE patients: an implicative protective mechanism and potential therapeutic strategy of systemic lupus erythematosus. Front. Immunol. 11, 579372 (2020).","journal-title":"Front. Immunol."},{"key":"1279_CR117","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders, H. J. et al. Lupus nephritis. Nat. Rev. Dis. Prim. 6, 7 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1279_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159751","volume":"7","author":"N Richoz","year":"2022","unstructured":"Richoz, N. et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight 7, e159751 (2022).","journal-title":"JCI Insight"},{"key":"1279_CR119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2023.03.030","volume":"104","author":"EJ Yoo","year":"2023","unstructured":"Yoo, E. J. et al. Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways. Kidney Int. 104, 163\u2013180 (2023).","journal-title":"Kidney Int."},{"key":"1279_CR120","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.molimm.2023.06.006","volume":"160","author":"J Tian","year":"2023","unstructured":"Tian, J. et al. S1P\/S1PR1 axis promotes macrophage M1 polarization through NLRP3 inflammasome activation in lupus nephritis. Mol. Immunol. 160, 55\u201366 (2023).","journal-title":"Mol. Immunol."},{"key":"1279_CR121","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.2147\/JIR.S489087","volume":"17","author":"M Tian","year":"2024","unstructured":"Tian, M. et al. Macrophage infiltration correlated with IFI16, EGR1 and MX1 expression in renal tubular epithelial cells within lupus nephritis-associated tubulointerstitial injury via bioinformatics analysis. J. Inflamm. Res. 17, 11469\u201311483 (2024).","journal-title":"J. Inflamm. Res."},{"key":"1279_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1321507","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Prediction of treatment response in lupus nephritis using density of tubulointerstitial macrophage infiltration. Front. Immunol. 15, 1321507 (2024).","journal-title":"Front. Immunol."},{"key":"1279_CR123","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-024-03311-y","volume":"26","author":"S Wei","year":"2024","unstructured":"Wei, S. et al. Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis. Arthritis Res. Ther. 26, 84 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"1279_CR124","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41586-024-07907-x","volume":"634","author":"SI Biniaris-Georgallis","year":"2024","unstructured":"Biniaris-Georgallis, S. I. et al. Amplification of autoimmune organ damage by NKp46-activated ILC1s. Nature 634, 952\u2013960 (2024).","journal-title":"Nature"},{"key":"1279_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06708-4","volume":"15","author":"W Li","year":"2024","unstructured":"Li, W. et al. Macrophages communicate with mesangial cells through the CXCL12\/DPP4 axis in lupus nephritis pathogenesis. Cell Death Dis. 15, 344 (2024).","journal-title":"Cell Death Dis."},{"key":"1279_CR126","doi-asserted-by":"publisher","first-page":"108278","DOI":"10.1016\/j.intimp.2021.108278","volume":"101","author":"J Tao","year":"2021","unstructured":"Tao, J., Zhao, J., Qi, X. M. & Wu, Y. G. Complement-mediated M2\/M1 macrophage polarization may be involved in crescent formation in lupus nephritis. Int. Immunopharmacol. 101, 108278 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1279_CR127","doi-asserted-by":"publisher","first-page":"300060521104996","DOI":"10.1177\/03000605211049963","volume":"49","author":"G Yang","year":"2021","unstructured":"Yang, G., Guo, N., Yin, J. & Wu, J. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J. Int. Med. Res. 49, 3000605211049963 (2021).","journal-title":"J. Int. Med. Res."},{"key":"1279_CR128","doi-asserted-by":"publisher","first-page":"935700","DOI":"10.3389\/fimmu.2022.935700","volume":"13","author":"YJ Huang","year":"2022","unstructured":"Huang, Y. J., Lin, C. H., Yang, H. Y., Luo, S. F. & Kuo, C. F. Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis. Front. Immunol. 13, 935700 (2022).","journal-title":"Front. Immunol."},{"key":"1279_CR129","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2020-219803","volume":"80","author":"DJ Wallace","year":"2021","unstructured":"Wallace, D. J., Figueras, F., Wegener, W. A. & Goldenberg, D. M. Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). Ann. Rheum. Dis. 80, 954\u2013955 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR131","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.2147\/IJN.S361400","volume":"17","author":"B Jiang","year":"2022","unstructured":"Jiang, B. et al. A tissue-tended mycophenolate-modified nanoparticle alleviates systemic lupus erythematosus in MRL\/Lpr mouse model mainly by promoting local M2-like macrophagocytes polarization. Int. J. Nanomed. 17, 3251\u20133267 (2022).","journal-title":"Int. J. Nanomed."},{"key":"1279_CR132","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000529931","volume":"15","author":"MY Mok","year":"2023","unstructured":"Mok, M. Y. et al. Interleukin-33 ameliorates murine systemic lupus erythematosus and is associated with induction of M2 macrophage polarisation and regulatory T cells. J. Innate Immun. 15, 485\u2013498 (2023).","journal-title":"J. Innate Immun."},{"key":"1279_CR133","first-page":"658","volume":"42","author":"W Nagata","year":"2024","unstructured":"Nagata, W. et al. Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus. Clin. Exp. Rheumatol. 42, 658\u2013665 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR134","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","volume":"402","author":"G Esp\u00edgol-Frigol\u00e9","year":"2023","unstructured":"Esp\u00edgol-Frigol\u00e9, G. et al. Polymyalgia rheumatica. Lancet 402, 1459\u20131472 (2023).","journal-title":"Lancet"},{"key":"1279_CR135","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5114\/reum.2021.110600","volume":"59","author":"E Hysa","year":"2021","unstructured":"Hysa, E., Ghorbannia, A., Emamifar, A., Milchert, M. & Manzo, C. Feasibility and usefulness of a fast-track clinic for patients suspected of polymyalgia rheumatica: notes for a work schedule through a narrative review of published literature. Reumatologia 59, 323\u2013329 (2021).","journal-title":"Reumatologia"},{"key":"1279_CR136","first-page":"123","volume":"29","author":"B Frediani","year":"2002","unstructured":"Frediani, B. et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J. Rheumatol. 29, 123\u2013130 (2002).","journal-title":"J. Rheumatol."},{"key":"1279_CR137","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/art.1780390719","volume":"39","author":"R Meliconi","year":"1996","unstructured":"Meliconi, R. et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 39, 1199\u20131207 (1996).","journal-title":"Arthritis Rheum."},{"key":"1279_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70045","volume":"7","author":"E Hysa","year":"2025","unstructured":"Hysa, E. et al. Soluble co-inhibitory immune checkpoint molecules are increased in patients with polymyalgia rheumatica without significant correlations with clinical status: a case-control study. ACR Open Rheumatol. 7, e70045 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1279_CR139","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard-2022-222873","volume":"82","author":"WF Jiemy","year":"2023","unstructured":"Jiemy, W. F. et al. Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica. Ann. Rheum. Dis. 82, 440\u2013442 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR140","doi-asserted-by":"publisher","first-page":"943574","DOI":"10.3389\/fimmu.2022.943574","volume":"13","author":"RD Reitsema","year":"2022","unstructured":"Reitsema, R. D. et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front. Immunol. 13, 943574 (2022).","journal-title":"Front. Immunol."},{"key":"1279_CR141","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","volume":"72","author":"C Dejaco","year":"2013","unstructured":"Dejaco, C. et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 72, 1852\u20131859 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR142","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ard.2025.01.004","volume":"84","author":"WF Jiemy","year":"2025","unstructured":"Jiemy, W. F. et al. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica. Ann. Rheum. Dis. 84, 833\u2013843 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201575","volume":"14","author":"RD Reitsema","year":"2023","unstructured":"Reitsema, R. D. et al. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica. Front. Immunol. 14, 1201575 (2023).","journal-title":"Front. Immunol."},{"key":"1279_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06826-4","volume":"7","author":"Y van Sleen","year":"2017","unstructured":"van Sleen, Y. et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis. Sci. Rep. 7, 6553 (2017).","journal-title":"Sci. Rep."},{"key":"1279_CR145","first-page":"S143","volume":"29","author":"R Caporali","year":"2011","unstructured":"Caporali, R., Cimmino, M. A., Montecucco, C. & Cutolo, M. Glucocorticoid treatment of polymyalgia rheumatica. Clin. Exp. Rheumatol. 29, S143\u2013S147 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR146","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5114\/reum\/170845","volume":"61","author":"E Hysa","year":"2023","unstructured":"Hysa, E. et al. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice. Reumatologia 61, 283\u2013293 (2023).","journal-title":"Reumatologia"},{"key":"1279_CR147","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco, C. et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 83, 48\u201357 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR148","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/rheumatology\/kead471","volume":"63","author":"E Hysa","year":"2024","unstructured":"Hysa, E. et al. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review. Rheumatology 63, 285\u2013297 (2024).","journal-title":"Rheumatology"},{"key":"1279_CR149","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.RES.84.9.1050","volume":"84","author":"HL Rittner","year":"1999","unstructured":"Rittner, H. L. et al. Tissue-destructive macrophages in giant cell arteritis. Circ. Res. 84, 1050\u20131058 (1999).","journal-title":"Circ. Res."},{"key":"1279_CR150","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002368","volume":"95","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2016","unstructured":"Hern\u00e1ndez-Rodr\u00edguez, J. et al. Description and validation of histological patterns and proposal of a dynamic model of inflammatory infiltration in giant-cell arteritis. Medicine 95, e2368 (2016).","journal-title":"Medicine"},{"key":"1279_CR151","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2665-9913(23)00300-4","volume":"6","author":"KSM van der Geest","year":"2024","unstructured":"van der Geest, K. S. M. et al. Large vessel giant cell arteritis. Lancet Rheumatol. 6, e397\u2013e408 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1279_CR152","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2665-9913(24)00024-9","volume":"6","author":"P Bosch","year":"2024","unstructured":"Bosch, P., Espigol-Frigol\u00e9, G., Cid, M. C., Mollan, S. P. & Schmidt, W. A. Cranial involvement in giant cell arteritis. Lancet Rheumatol. 6, e384\u2013e396 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1279_CR153","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/keae043","volume":"64","author":"P Seitz","year":"2025","unstructured":"Seitz, P. et al. Musculoskeletal magnetic resonance imaging findings support a common spectrum of giant cell arteritis and polymyalgia rheumatica. Rheumatology 64, 321\u2013331 (2025).","journal-title":"Rheumatology"},{"key":"1279_CR154","doi-asserted-by":"publisher","first-page":"564","DOI":"10.55563\/clinexprheumatol\/vn1qbp","volume":"39","author":"A Sobrero","year":"2021","unstructured":"Sobrero, A. et al. Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre. Clin. Exp. Rheumatol. 39, 564\u2013569 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1279_CR155","doi-asserted-by":"publisher","unstructured":"Hysa, E. et al. Environmental factors in polymyalgia rheumatica and giant cell arteritis. J. Environ. Rheumatol. https:\/\/doi.org\/10.55563\/jer\/ztobhu (2025).","DOI":"10.55563\/jer\/ztobhu"},{"key":"1279_CR156","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","volume":"19","author":"A Tomelleri","year":"2023","unstructured":"Tomelleri, A. et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat. Rev. Rheumatol. 19, 446\u2013459 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1279_CR157","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/annrheumdis-2024-eular.677","volume":"83","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Overlapping macrophage profiles in PMR bursa and GCA temporal artery biopsies [POS0270]. Ann. Rheum. Dis. 83, 277\u2013278 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR158","doi-asserted-by":"publisher","first-page":"859502","DOI":"10.3389\/fimmu.2022.859502","volume":"13","author":"R Watanabe","year":"2022","unstructured":"Watanabe, R. & Hashimoto, M. Pathogenic role of monocytes\/macrophages in large vessel vasculitis. Front. Immunol. 13, 859502 (2022).","journal-title":"Front. Immunol."},{"key":"1279_CR159","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K","volume":"42","author":"JS Johansen","year":"1999","unstructured":"Johansen, J. S. et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 42, 2624\u20132630 (1999).","journal-title":"Arthritis Rheum."},{"key":"1279_CR160","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/cells13030267","volume":"13","author":"M Paroli","year":"2024","unstructured":"Paroli, M., Caccavale, R. & Accapezzato, D. Giant cell arteritis: advances in understanding pathogenesis and implications for clinical practice. Cells 13, 267 (2024).","journal-title":"Cells"},{"key":"1279_CR161","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/CIRCRESAHA.122.322128","volume":"132","author":"CM Weyand","year":"2023","unstructured":"Weyand, C. M. & Goronzy, J. J. Immunology of giant cell arteritis. Circ. Res. 132, 238\u2013250 (2023).","journal-title":"Circ. Res."},{"key":"1279_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101012","volume":"4","author":"S Ohtsuki","year":"2023","unstructured":"Ohtsuki, S. et al. Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis. Cell Rep. Med. 4, 101012 (2023).","journal-title":"Cell Rep. Med."},{"key":"1279_CR163","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.3390\/jcm10214958","volume":"10","author":"I Esen","year":"2021","unstructured":"Esen, I. et al. Functionally heterogenous macrophage subsets in the pathogenesis of giant cell arteritis: novel targets for disease monitoring and treatment. J. Clin. Med. 10, 4958 (2021).","journal-title":"J. Clin. Med."},{"key":"1279_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102684","volume":"123","author":"JC Graver","year":"2021","unstructured":"Graver, J. C. et al. Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. J. Autoimmun. 123, 102684 (2021).","journal-title":"J. Autoimmun."},{"key":"1279_CR165","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/art.41887","volume":"73","author":"Y van Sleen","year":"2021","unstructured":"van Sleen, Y. et al. A distinct macrophage subset mediating tissue destruction and neovascularization in giant cell arteritis: implication of the YKL-40\/interleukin-13 receptor \u03b12 axis. Arthritis Rheumatol. 73, 2327\u20132337 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1279_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1164","volume":"9","author":"WF Jiemy","year":"2020","unstructured":"Jiemy, W. F. et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clin. Transl. Immunol. 9, e1164 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"1279_CR167","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1172\/JCI118959","volume":"98","author":"CM Weyand","year":"1996","unstructured":"Weyand, C. M., Wagner, A. D., Bj\u00f6rnsson, J. & Goronzy, J. J. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J. Clin. Invest. 98, 1642\u20131649 (1996).","journal-title":"J. Clin. Invest."},{"key":"1279_CR168","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.autrev.2017.05.004","volume":"16","author":"F Ciccia","year":"2017","unstructured":"Ciccia, F. et al. New insights into the pathogenesis of giant cell arteritis. Autoimmun. Rev. 16, 675\u2013683 (2017).","journal-title":"Autoimmun. Rev."},{"key":"1279_CR169","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/ard-2023-224467","volume":"83","author":"D Veroutis","year":"2024","unstructured":"Veroutis, D. et al. Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways. Ann. Rheum. Dis. 83, 342\u2013350 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR170","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.42525","volume":"75","author":"WF Jiemy","year":"2023","unstructured":"Jiemy, W. F. et al. Indication of activated senescence pathways in the temporal arteries of patients with giant cell arteritis. Arthritis Rheumatol. 75, 1812\u20131818 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1279_CR171","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard-2023-225270","volume":"83","author":"M Karabayas","year":"2024","unstructured":"Karabayas, M. et al. Vascular disease persistence in giant cell arteritis: are stromal cells neglected? Ann. Rheum. Dis. 83, 1100\u20131109 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR172","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/acr.25354","volume":"76","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Altered plasma levels and tissue expression of fibroblast activation protein alpha in giant cell arteritis. Arthritis Care Res. 76, 1322\u20131332 (2024).","journal-title":"Arthritis Care Res."},{"key":"1279_CR173","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/modpathol.2017.10","volume":"30","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski, J. J. et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod. Pathol. 30, 788\u2013796 (2017).","journal-title":"Mod. Pathol."},{"key":"1279_CR174","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1093\/rheumatology\/kead061","volume":"62","author":"E Cantoni","year":"2023","unstructured":"Cantoni, E. et al. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production. Rheumatology 62, 3469\u20133479 (2023).","journal-title":"Rheumatology"},{"key":"1279_CR175","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005132","volume":"10","author":"C Ricordi","year":"2024","unstructured":"Ricordi, C. et al. Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies. RMD Open. 10, e005132 (2024).","journal-title":"RMD Open."},{"key":"1279_CR176","doi-asserted-by":"publisher","first-page":"1759720x2210963","DOI":"10.1177\/1759720X221096366","volume":"14","author":"M Bond","year":"2022","unstructured":"Bond, M., Tomelleri, A., Buttgereit, F., Matteson, E. L. & Dejaco, C. Looking ahead: giant-cell arteritis in 10 years time. Ther. Adv. Musculoskelet. Dis. 14, 1759720x221096366 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1279_CR177","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","volume":"81","author":"M Corbera-Bellalta","year":"2022","unstructured":"Corbera-Bellalta, M. et al. Blocking GM-CSF receptor \u0251 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann. Rheum. Dis. 81, 524\u2013536 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR178","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid, M. C. et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 653\u2013661 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1279_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265196","volume":"17","author":"D Unuvar Purcu","year":"2022","unstructured":"Unuvar Purcu, D. et al. Effect of stimulation time on the expression of human macrophage polarization markers. PLoS ONE 17, e0265196 (2022).","journal-title":"PLoS ONE"},{"key":"1279_CR180","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/JLB.3RU1018-378RR","volume":"106","author":"LX Wang","year":"2019","unstructured":"Wang, L. X., Zhang, S. X., Wu, H. J., Rong, X. L. & Guo, J. M2b macrophage polarization and its roles in diseases. J. Leukoc. Biol. 106, 345\u2013358 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"1279_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111729","volume":"14","author":"K Ishida","year":"2023","unstructured":"Ishida, K. et al. Induction of unique macrophage subset by simultaneous stimulation with LPS and IL-4. Front. Immunol. 14, 1111729 (2023).","journal-title":"Front. Immunol."},{"key":"1279_CR182","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1093\/rheumatology\/keae710","volume":"64","author":"N Watanabe","year":"2025","unstructured":"Watanabe, N. et al. Tissue degrading and remodelling molecules in giant cell arteritis. Rheumatology 64, 3095\u20133103 (2025).","journal-title":"Rheumatology"},{"key":"1279_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03234-3","volume":"23","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Jin, X., Fu, N. & Li, J. Medrysone promotes corneal injury repair by promoting M2-like polarization of macrophages. BMC Ophthalmol. 23, 503 (2023).","journal-title":"BMC Ophthalmol."},{"key":"1279_CR184","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.3390\/ijms24108757","volume":"24","author":"H Williams","year":"2023","unstructured":"Williams, H. et al. Monocyte differentiation and heterogeneity: inter-subset and interindividual differences. Int. J. Mol. Sci. 24, 8757 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1279_CR185","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41590-022-01205-2","volume":"23","author":"I Visan","year":"2022","unstructured":"Visan, I. Monocytes as targets. Nat. Immunol. 23, 645 (2022).","journal-title":"Nat. Immunol."},{"key":"1279_CR186","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev-immunol-042718-041728","volume":"37","author":"K Bassler","year":"2019","unstructured":"Bassler, K., Schulte-Schrepping, J., Warnat-Herresthal, S., Aschenbrenner, A. C. & Schultze, J. L. The myeloid cell compartment \u2014 cell by cell. Annu. Rev. Immunol. 37, 269\u2013293 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"1279_CR187","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/ATVBAHA.117.309145","volume":"37","author":"GD Thomas","year":"2017","unstructured":"Thomas, G. D. et al. Human blood monocyte subsets: a new gating strategy defined using cell surface markers identified by mass cytometry. Arterioscler. Thromb. Vasc. Biol. 37, 1548\u20131558 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1279_CR188","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","volume":"118","author":"KL Wong","year":"2011","unstructured":"Wong, K. L. et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118, e16\u2013e31 (2011).","journal-title":"Blood"},{"key":"1279_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100846","volume":"4","author":"CK Hall","year":"2024","unstructured":"Hall, C. K. et al. Profiling migration of human monocytes in response to chemotactic and barotactic guidance cues. Cell Rep. Methods 4, 100846 (2024).","journal-title":"Cell Rep. Methods"},{"key":"1279_CR190","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313\u2013326 (2009).","journal-title":"J. Interferon Cytokine Res."},{"key":"1279_CR191","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.349","volume":"4","author":"M Li","year":"2023","unstructured":"Li, M. et al. Signaling pathways in macrophages: molecular mechanisms and therapeutic targets. MedComm (2020) 4, e349 (2023).","journal-title":"MedComm (2020)"},{"key":"1279_CR192","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1073\/pnas.85.8.2805","volume":"85","author":"MT Quinn","year":"1988","unstructured":"Quinn, M. T., Parthasarathy, S. & Steinberg, D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl Acad. Sci. USA 85, 2805\u20132809 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1279_CR193","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","volume":"17","author":"M Metzemaekers","year":"2020","unstructured":"Metzemaekers, M., Gouwy, M. & Proost, P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell. Mol. Immunol. 17, 433\u2013450 (2020).","journal-title":"Cell. Mol. Immunol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01279-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01279-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01279-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:16:23Z","timestamp":1757308583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01279-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":193,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01279-w","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"20 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}